Summary:
Depression is a persistent whole-body illness
Feeling sad, low in energy, distracted, or unable to focus can be a normal response to discouraging events; the distinction is that most people recover, whereas depression can persist for years without effective treatment.
Depression involves emotions, thoughts, and behavior, but its effects are not confined to the mind: stress and inflammation can contribute to its onset, and inflammation in the body can promote inflammation in the brain. The relationship can become a vicious cycle: brain inflammation can worsen depression, while depression can intensify inflammation in the body.
- Inadequately treated depression is associated in the interview with worse outcomes from heart, respiratory, kidney, and cerebrovascular disease, and with dying as much as 10 years early.
- Depression also increases the risk of self-harm and suicide, making it a serious medical illness for which people should seek help.
A shift from monoamines to glutamate circuits
Earlier biological accounts often focused on serotonin and norepinephrine because many familiar antidepressants act on those chemical systems: selective serotonin reuptake inhibitors (SSRIs), such as Prozac and Zoloft, target serotonin, while other medications target norepinephrine-related signaling. However, studies that depleted serotonin and norepinephrine without causing depression challenged the idea that depression is simply a deficiency of those neurotransmitters.
This led the researchers to consider whether antidepressants might help by recruiting resilience systems rather than directly reversing the underlying biology of depression. They turned attention to higher brain regions involved in emotion and cognition, including the cerebral cortex and limbic system, which rely heavily on glutamate—the main excitatory chemical messenger used at roughly 70% or more of brain synapses.
Key conceptual shift: Instead of treating depression solely as a problem of serotonin or norepinephrine, this research probed glutamate circuits and the brain systems that support emotion, cognition, and resilience.
The researchers used a low dose of ketamine, an anesthetic known since the 1960s, to block some N-methyl-D-aspartate (NMDA) glutamate receptors and examine effects on behavior and cognition. In depressed patients, ketamine’s immediate mood and cognitive effects wore off with the drug, but some patients began feeling better about four hours later, and some were back to themselves by the next morning.
Ketamine’s rapid antidepressant effect and clinical use
The rapid improvement was replicated by other research groups, and ketamine was found to be effective for treatment-resistant depression—depressive symptoms that persist despite treatment. Johnson & Johnson developed esketamine, the “S” mirror-image form, which was approved by the United States Food and Drug Administration (FDA) in 2019 for treatment-resistant depression.
| Treatment detail | What the interview reports |
|---|
| Esketamine | The S isomer of ketamine; FDA-approved for treatment-resistant depression in 2019. |
| Racemic ketamine | A mixture of the R and S isomers; described as an FDA-approved anesthetic, but not approved for depression treatment. |
| R isomer | Reported as two to five times less potent at the NMDA receptor than the S isomer; the interview says higher doses might be needed, but that the company had not used doses high enough to show effectiveness. |
| Relative treatment claims | The speaker describes esketamine as the most rapidly effective FDA-approved depression treatment, about twice as effective as the next approach for treatment-resistant symptoms, and about twice as good at preventing relapse in long-term treatment as standard antidepressants. |
The speaker also mentions preliminary long-term data suggesting possible reductions in suicide attempts, suicide deaths, and all-cause mortality, while presenting these as findings that still require caution. The treatment has expanded into clinic-based care; the interview reports about 6,000 clinics in the United States offering ketamine or esketamine, with coverage from Medicaid, Medicare, and private insurance discussed for treatment access.
How ketamine may support recovery in the brain
The euphoric effects of ketamine fade before its antidepressant effects emerge, so the speaker distinguishes the drug’s transient subjective effects from the longer-lasting recovery process. The account is described as complex and still evolving, but it highlights brain-derived neurotrophic factor (BDNF), a nerve growth factor that helps the brain cope with stress.
Stress can reduce synaptic connections—the communication links between nerve cells—and make some connections less effective by removing glutamate receptors from synapses. Ketamine is described as supporting recovery in two related ways: it shifts the balance toward synaptic growth rather than elimination, and it helps restore glutamate receptors to existing synapses, improving their communication.
Proposed Brain Recovery Pathway for Ketamine
The proposed synaptic changes help explain why the benefit can outlast ketamine’s presence in the body but may fade as regrown connections diminish; the speaker links this limited persistence to the need for frequent treatment at the start. Ketamine is therefore framed as recruiting the brain’s own resilience mechanisms, rather than simply acting like a conventional daily antidepressant.
Treatment sessions, monitoring, and safety
Treatment is generally delivered in a clinic in sessions of about two hours, often twice weekly at the beginning to prevent symptoms from breaking through between visits. As symptoms stabilize, treatment frequency may be reduced, commonly to weekly or every other week, and sometimes less often. Because ketamine remains in the body for a relatively short time, the speaker says patients generally do not experience its drug effects throughout everyday life, unlike some treatments with ongoing side effects.
During treatment, patients may experience nausea or vomiting, or increased blood pressure; the speaker says additional medication can be given to manage these effects under clinical monitoring. Clinic administration is also intended to reduce misuse risk: the interview describes a person taking ketamine six to eight times a day from a bottle, rather than following a treatment schedule, and warns that taking more or using it more often than needed can create addiction problems.
Route and dose control matter. The speaker says ketamine is not well absorbed orally, while intravenous delivery allows blood levels to be controlled carefully; the developed esketamine product is a fine intranasal spray absorbed through the sinus, intended to provide more consistent absorption than drops that run down the throat.
Who may be considered and how care is coordinated
The interview identifies two groups as good candidates for ketamine or esketamine: people with treatment-resistant symptoms after trying antidepressants, and people who are urgently ill, such as those who are not eating, are in very poor condition, or are at high risk of suicide. For people who are urgently ill, the speaker says they may not need to try several other medications before ketamine or esketamine is considered.
People already receiving care are advised to discuss the option with their doctor or nurse practitioner and, if appropriate, seek referral to a clinic that can coordinate with their existing treatment team. The interview emphasizes collaboration between the ongoing clinician and ketamine-clinic clinician so care remains continuous rather than fragmented.
If someone feels suicidal or might harm themselves, the speaker advises getting to a safe place; for many people, that may mean going to an emergency room, where help can connect them with a ketamine clinic if appropriate. The interview also notes that many academic medical centers have ketamine treatment programs.
Treatment duration, maintenance, and coverage
The length of treatment varies: some people receive one or two months of treatment and then taper or stop, while others need ongoing sessions to sustain improvement. The speaker cites data from people who continued treatment for an average of 42 months, with very good outcomes reported in that group.
A common approach is to begin with more frequent sessions and gradually increase the time between them; if symptoms return after sessions are spaced too far apart, increasing treatment frequency again may help those symptoms resolve. The appropriate schedule is described as a partnership between the patient and treating clinician.
Esketamine is generally covered by insurance, according to the interview. Racemic ketamine is approved as an anesthetic rather than for depression, and the speaker says coverage for its intravenous use is uncommon nationally, though some plans at Yale New Haven Hospital cover it.
Emerging research: immune cells and longer-lasting effects
Researchers are studying other versions of ketamine that target particular subtypes within the NMDA receptor family. A company the speaker is involved with is also developing a combination of ketamine and an immune-modulating drug; early findings suggest the combination might lengthen the effect of each dose and potentially reduce dosing from twice weekly to once every two weeks, but the work is at an early development stage.
A proposed biological link involves microglia, immune cells in the brain that the speaker describes as hyperactive in depression. When hyperactive, microglia can surround and engulf synaptic connections; the interview also says they can harm the insulating white matter around nerve fibers and affect the brain’s support cells, called glia.
The proposed immune-modulating strategy is intended to shift microglia away from a depression-promoting state and toward releasing BDNF and protecting the brain, potentially helping ketamine or esketamine promote recovery. The speaker presents this as a developing hypothesis, not an established clinical result.
Research examples described in the interview support a role for microglia in ketamine’s antidepressant effects: studies in animals found that removing microglia blocked those effects, and a study that selectively blocked the BDNF gene in microglia also blocked them. This suggests, in the account presented, that microglia may be an important source of the BDNF involved in regrowing synaptic connections, connecting immune biology with neuroscience.
